Patent 11014982

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Diane D. Harrison (Janssen Biotech Inc)
  • Elizabeth C. Hsia (Janssen Biotech Inc)
  • Lee-Lian Kim (Janssen Biotech Inc)
  • Kim Hung Lo (Janssen Biotech Inc)

Original assignee

Janssen Biotech Inc is a pharmaceutical company that develops and commercializes biologic products, including anti-TNF antibodies. They ship products embodying the claims of this patent (e.g., SIMPONI® (golimumab), which is an anti-TNF-alpha monoclonal antibody for the treatment of various inflammatory conditions, including ankylosing spondylitis). Janssen Biotech Inc is currently operating as a subsidiary of Johnson & Johnson.

Assignment timeline

No assignments are recorded for US11014982 in the USPTO Assignment Center.

Timeline diagram

timeline
    title Ownership of US 11014982
    2019 : Filed by Janssen Biotech Inc
    2021 : Issued to Janssen Biotech Inc

NPE / troll-pattern signals

  1. Shell-entity transfer — not present
  2. Known asserter in the chain — not present
  3. Repeat correspondent across the chain — not present
  4. Cascading transfers — not present
  5. Pre-litigation transfer — not present
  6. Bankruptcy fire-sale — not present
  7. Privateering — not present
  8. Defensive aggregator (anti-NPE) — not present

Verdict

Operating-company assertion. The patent was filed and issued to Janssen Biotech Inc, an operating pharmaceutical company that markets products relevant to the patent's claims. There are no recorded assignments of this patent in the USPTO Assignment Center, indicating that ownership likely remains with the original assignee. The ongoing litigation in Delaware District Court (case 1:26-cv-00222) and the PTAB case (IPR2026-00256) suggest active assertion by Janssen Biotech Inc.

USPTO Assignment Center Search for US11014982

Generated 5/29/2026, 5:53:12 PM